# Rallybio (RLYB) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/RLYB
## Company Profile
- Ticker: RLYB
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Rare Disease
## Stock Data
- Close: 16.875 USD
- Market cap: 94134000 USD
- Last updated: 2026-09-03
## Business Overview
Rallybio is a rare-disease biotechnology company focused on complement and immune-mediated disorders. Its pipeline aims at high-unmet-need conditions where targeted biology matters.
## Why The Stock Is Moving

As of Sep 3, 2026, RLYB closed down 0.38% at $16.88. No new same-company headline was identified in the current news window.

## Geographic Base

Headquartered in the United States and listed on NASDAQ, Rallybio sits in specialty biotechnology.

## Business Model

The business depends on clinical proof, pipeline selection, and the ability to create value in rare-disease markets.

## Landscape Position

Rallybio is a rare-disease catalyst name whose valuation is closely linked to proof-of-concept and strategy.

## Future Catalysts

- Rallybio’s catalysts are its complement and rare-disease programs, especially whether the company can keep progressing toward a clearer clinical path. The stock tends to respond quickly if the next update shows the platform still has room to run.

## Recent News
- 2026-06-01 12:00 EST — [Rallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private Placement](https://biopharmsignal.com/news/RLYB/rallybio-corporation-and-avenzo-therapeutics-announce-merger-agreement-to-advance-next-generation-oncology-therapies-and-215-million-concurrent-private-placement) — Source: Rallybio
- 2026-03-02 13:00 EST — [Rallybio Corporation and Candid Therapeutics Announce Merger Agreement](https://biopharmsignal.com/news/RLYB/rallybio-corporation-and-candid-therapeutics-announce-merger-agreement) — Source: Rallybio
- 2026-02-17 13:00 EST — [Rallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal Complement](https://biopharmsignal.com/news/RLYB/rallybio-announces-positive-data-for-rlyb116-phase-1-study-demonstrating-complete-and-sustained-inhibition-of-terminal-complement) — Source: Rallybio
- 2026-02-03 21:05 EST — [Rallybio Announces Reverse Stock Split of Common Stock](https://biopharmsignal.com/news/RLYB/rallybio-announces-reverse-stock-split-of-common-stock) — Source: Rallybio
- 2025-11-06 13:00 EST — [Rallybio Reports Third Quarter 2025 Financial Results and Provides Business Updates](https://biopharmsignal.com/news/RLYB/rallybio-reports-third-quarter-2025-financial-results-and-provides-business-updates) — Source: Rallybio